四分位间距
生物标志物
医学
肺结核
代谢组学
接收机工作特性
肺癌
生物标志物发现
曲线下面积
诊断生物标志物
内科学
癌症
多元分析
肿瘤科
胃肠病学
病理
生物信息学
蛋白质组学
生物
基因
生物化学
作者
Siyu Chen,Chunyan Li,Zhonghua Qin,Song Lili,Shiyuan Zhang,Chongxiang Sun,Pengwei Zhuang,Yuming Wang,Bin Yang,Li Ning,Yubo Li
标识
DOI:10.1093/infdis/jiad175
摘要
Abstract Background Pulmonary tuberculosis (PTB) and lung cancer (LC) have similar clinical symptoms and atypical imaging findings, which are easily misdiagnosed. There is an urgent need for a noninvasive and accurate biomarker to distinguish LC from PTB. Methods A total of 694 subjects were enrolled and divided into discovery set (n = 122), identification set (n = 214), and validation set (n = 358). Metabolites were identified by multivariate and univariate analyses. Receiver operating characteristic curve were used to evaluate the diagnostic efficacy of biomarkers. Results Seven metabolites were identified and validated. Phenylalanylphenylalanine for distinguishing LC from PTB yielded an area under the curve of 0.89, sensitivity of 71%, and specificity of 92%. It also showed good diagnostic abilities in discovery set and identification set. Compared with that in healthy volunteers (median [interquartile range], 1.57 [1.01, 2.34] μg/mL), it was elevated in LC (4.76 [2.74, 7.08] μg/mL; ratio of median, [ROM] = 3.03, P < .01) and reduced in PTB (1.06 [0.51, 2.09] μg/mL; ROM = 0.68, P < .05). Conclusions The metabolomic profile of LC and PTB was described and a key biomarker identified. We produced a rapid and noninvasive method to supplement existing clinical diagnostic examinations for distinguishing LC from PTB.
科研通智能强力驱动
Strongly Powered by AbleSci AI